Nivolumab in real-life clinical practice
| العنوان: | Nivolumab in real-life clinical practice |
|---|---|
| المؤلفون: | M. A. Lyadova, O. A. Pardabekova, R. R. Shakirov, V. K. Lyadov, M. Yu. Fedyanin |
| المصدر: | Issledovaniâ i Praktika v Medicine, Vol 6, Iss 4, Pp 84-91 (2019) |
| بيانات النشر: | QUASAR, LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, Colorectal cancer, General Arts and Humanities, Melanoma, immune therapy, nivolumab, melanoma, non-small cell lung cancer, metastatic colorectal cancer, real-life clinical practice, medicine.disease, Gastroenterology, Clinical trial, 03 medical and health sciences, 0302 clinical medicine, Tolerability, 030220 oncology & carcinogenesis, Internal medicine, Carcinoma, Medicine, 030211 gastroenterology & hepatology, Nivolumab, business, Adverse effect, Pneumonitis |
| الوصف: | Purpose of the study . To evaluate the efficacy and tolerability of nivolumab in oncologic patients in real-life clinical seffings. Patients and methods . Analysis included 114 patients aged 26-96 years with melanoma ( n = 64), non-small cell lung carcinoma (NSCLC) ( n = 37) and metastatic colorectal cancer with high levels of microsatellite instability (MSI-H mCRC) ( n = 13), receiving immune checkpoint therapy with nivolumab (3 mg/kg every 14 days). All patients underwent comprehensive examination including CT/chest radiography, CT/MRI/ultrasound of abdominal organs or PET-CT of the whole body and other investigations if necessary. Efficacy of treatment was assessed after every 6 courses on treatment or in case of signs of clinical progression. Treatment response was assessed using iRECIST 1.1 criteria. Results . Among patients with metastatic melanoma positive for BRAF gene mutation, receiving immune therapy objective treatment response was registered in 13.6%, tumor control — in 27.2%. In the group of patients, negative for BRAF gene mutation objective response was achieved in 27.5%, tumor control — in 41.4% patients. None of mCRC patients in our group achieved objective response, stable disease was observed in 30.8% of patients, progression — in 38.5% and unconfirmed progression — in 7.7% of patients. In NSCLC group complete response was observed in 2.7%, partial response — in 2.7%, stabilization — in 27.1%, unconfirmed progression — in 5.4%, progression — in 29.7% of patients. Safety analysis revealed the following significant adverse reactions: thyroiditis (n = 3), pneumonitis of 3 grade (n = 1), hepatitis of 3 grade (n = 1) and arthritis of 2 grade (n = 1). In 4 patients adverse reactions required treatment delay and prescription of glucocorticoids. Conclusion . Nivolumab treatment in real-life clinical practice is associated with a lower prevalence of adverse events compared to the results of clinical trials. |
| تدمد: | 2410-1893 2409-2231 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5744c9b6afcd55e57e6e12715212c8Test https://doi.org/10.17709/2409-2231-2019-6-4-8Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fa5744c9b6afcd55e57e6e12715212c8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 24101893 24092231 |
|---|